Eli Lilly Stock Surges on Obesity-Drug Boom – Is $1,000 Next?
Eli Lilly shares surged nearly 9% to $832 intraday on Oct. 1 after closing at $763 on Sept. 30, driven by bullish options activity and optimism over its weight-loss and Alzheimer’s drugs. Q2 revenue jumped 38% to $15.56 billion, powered by GLP-1 treatments Mounjaro and ZepBound. The company raised full-year sales guidance to $60–$62 billion. Lilly faces a lawsuit from Texas over alleged incentives for prescriptions, which it denies.
